Adial Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Coastlands Capital LP reported changes in beneficial ownership of Adial Pharmaceuticals, Inc. common stock on July 14, 2026.
NASDAQ
Coastlands Capital LP reported changes in beneficial ownership of Adial Pharmaceuticals, Inc. common stock on July 9, 2026.
NASDAQ
Coastlands Capital LP reports the acquisition of 25,000 shares of ADial Pharmaceuticals, Inc. common stock.
NASDAQ
Matt Davidson, Chief Development Officer and Director at Adial Pharmaceuticals, reports significant stock transactions following a merger.
NASDAQ
Director Wendy B. Young of Adial Pharmaceuticals, Inc. has acquired 36,378 pre-funded warrants for common stock, as detailed in a recent SEC Form 4 filing.
NASDAQ
Tony Goodman, Chief Operating Officer of ADial Pharmaceuticals, Inc., reported the acquisition of 26,510 shares of common stock on April 7, 2026, as part of a restricted stock grant.
NASDAQ
Kevin Schuyler, a Director at ADial Pharmaceuticals, Inc., has acquired 9,185 shares of common stock through a restricted stock grant.
NASDAQ
Vinay Shah, Chief Financial Officer of ADial Pharmaceuticals, Inc., received a grant of 17,325 restricted shares of common stock.
NASDAQ
Robertson H. Gilliland, a Director at ADIAL PHARMACEUTICALS, INC., reported the acquisition of 9,185 shares of common stock on April 7, 2026.
NASDAQ
ADial Pharmaceuticals reports a restricted stock grant to CEO Cary J. Claiborne, vesting in one year or upon change of control.
NASDAQ
ADIAL Pharmaceuticals' Chief Financial Officer, Vinay Shah, was granted 9,000 stock options with an exercise price of $0.688, vesting monthly over 36 months starting May 29, 2025.
NASDAQ
Adial Pharmaceuticals, Inc. director and 10% owner Robertson H. Gilliland was granted 28,000 stock options with an exercise price of $0.688, vesting monthly over 36 months.
NASDAQ
Adial Pharmaceuticals, Inc. director James W. Newman, Jr. was granted 28,000 stock options with an exercise price of $0.688, vesting over 36 months.
NASDAQ
ADIAL Pharmaceuticals, Inc. director Kevin Schuyler was granted 28,000 stock options with an exercise price of $0.688, vesting monthly over 36 months.
NASDAQ
ADIAL Pharmaceuticals' CEO, Cary J. Claiborne, was granted 138,000 stock options with an exercise price of $0.688, vesting over 36 months.
NASDAQ
ADIAL Pharmaceuticals, Inc. Chief Operating Officer and Director Tony Goodman was granted 94,000 stock options with an exercise price of $0.688 per share, vesting over 36 months.
NASDAQ
ADIAL PHARMACEUTICALS, INC. Director J. Kermit Anderson has been granted 28,000 stock options with an exercise price of $0.688, vesting monthly over 36 months.
NASDAQ
Adial Pharmaceuticals' CEO, Cary J. Claiborne, was granted 350,000 stock options on December 5, 2024, which vest monthly over 36 months.
NASDAQ
Adial Pharmaceuticals' Chief Financial Officer, Vinay Shah, was granted 40,000 stock options on November 16, 2024.
NASDAQ
Robertson H. Gilliland, a director of Adial Pharmaceuticals, acquired stock options exercisable for 12,000 shares of common stock.
NASDAQ
James W. Newman, Jr., a director of Adial Pharmaceuticals, Inc., acquired stock options on March 25, 2024.
NASDAQ
Joseph Truluck, CFO of Adial Pharmaceuticals, acquired 25,000 stock options on March 25, 2024, according to a Form 4 filing.
NASDAQ
Cary J. Claiborne, CEO of Adial Pharmaceuticals, acquired 60,000 stock options on March 25, 2024.
NASDAQ
Director J. Kermit Anderson acquired stock options in Adial Pharmaceuticals, Inc. on March 25, 2024.
NASDAQ
Director Kevin Schuyler acquired stock options in Adial Pharmaceuticals, Inc. on March 25, 2024.
NASDAQ
Tony Goodman, Chief Operating Officer of Adial Pharmaceuticals, acquired 42,000 stock options on March 25, 2024.